BMEA Stock Price, Biomea Fusion, Inc. Quote, Chart

Market Summary

USD12.34+0.89

Market Closed

7.77%

BMEA Stock Price

View Fullscreen

BMEA RSI Chart

BMEA Valuation

Market Cap

443.6M

Price/Earnings (Trailing)

-3.49

Price/Sales (Trailing)

44.81

Price/Free Cashflow

-4.22

BMEA Price/Sales (Trailing)

BMEA Profitability

Return on Equity

-94.05%

Return on Assets

-75.53%

Free Cashflow Yield

-23.69%

BMEA Fundamentals

BMEA Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

103.88%

Rev. Growth (Qtr)

-18.25%

BMEA Earnings

Earnings (TTM)

-127.3M

Earnings Growth (Yr)

-34.46%

Earnings Growth (Qtr)

-11.97%

Breaking Down BMEA Revenue

Last 7 days

-6.4%

Last 30 days

-11.6%

Last 90 days

-31.3%

Trailing 12 Months

-66.2%

How does BMEA drawdown profile look like?

BMEA Financial Health

Current Ratio

5.84

BMEA Investor Care

Shares Dilution (1Y)

1.54%

Diluted EPS (TTM)

-3.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.9M	0	0	0
2023	2.8M	5.3M	7.4M	8.9M
2022	129.0K	309.0K	871.0K	1.8M
2021	26.7K	50.3K	74.0K	100.0K
2020	0	0	0	3.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biomea Fusion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 29, 2023	erdtmann rainer m	gifted	-	-	-21,000	president and coo
Dec 29, 2023	erdtmann rainer m	gifted	-	-	3,000	president and coo
Dec 29, 2023	erdtmann rainer m	gifted	-	-	6,000	president and coo
Nov 30, 2023	valle franco	acquired	5,087	3.7825	1,345	chief financial officer
Jun 01, 2023	a2a pharmaceuticals, inc.	sold	-1,728,160	34.5633	-50,000	-
May 31, 2023	a2a pharmaceuticals, inc.	sold	-2,535,750	33.81	-75,000	-
May 31, 2023	valle franco	acquired	16,162	3.7825	4,273	chief financial officer
May 12, 2023	a2a pharmaceuticals, inc.	sold	-846,000	33.84	-25,000	-
May 09, 2023	a2a pharmaceuticals, inc.	sold	-5,175,720	34.5048	-150,000	-
May 08, 2023	a2a pharmaceuticals, inc.	sold	-3,399,310	33.9931	-100,000	-

Which funds bought or sold BMEA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Nuveen Asset Management, LLC	unchanged	-	23,730	825,002	-%
May 13, 2024	Balyasny Asset Management L.P.	added	20.94	79,849	405,504	-%
May 13, 2024	NATIXIS	added	65.25	126,316	297,180	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	706	24,533	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-1,317,000	-	-%
May 13, 2024	Jump Financial, LLC	reduced	-62.05	-272,295	174,616	-%
May 13, 2024	FMR LLC	unchanged	-	2,303,020	80,070,200	-%
May 13, 2024	E Fund Management Co., Ltd.	new	-	337,945	337,945	0.02%
May 13, 2024	Rafferty Asset Management, LLC	added	370	5,675,210	7,151,590	0.03%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	2.77	405,964	7,381,060	-%

Are Funds Buying or Selling BMEA?

Are funds buying BMEA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BMEA

No. of Funds

Unveiling Biomea Fusion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	12.50%	4,485,615	SC 13G
Feb 14, 2024	baker bros. advisors lp	5.9%	2,108,949	SC 13G/A
Feb 12, 2024	butler thomas andrew	10.4%	3,802,482	SC 13G/A
Feb 12, 2024	erdtmann rainer m	7.8%	2,820,900	SC 13G/A
Feb 12, 2024	janus henderson group plc	4.8%	1,718,245	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	laurion capital management lp	7.66%	2,736,367	SC 13G
Jan 29, 2024	blackrock inc.	6.0%	2,156,342	SC 13G
May 10, 2023	fmr llc	-	0	SC 13G
Apr 03, 2023	cormorant global healthcare master fund, lp	5.08%	1,795,928	SC 13D/A

Recent SEC filings of Biomea Fusion, Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Biomea Fusion, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	6.22%	110.41%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-16.95%	-51.10%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	9.36%	-4.29%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-10.69%	-43.90%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Biomea Fusion, Inc. News

Latest updates

Biomea Fusion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-18.2%	1,998	2,444	2,690	2,766	980	962	594	216	34.00	27.00	32.00	36.00	5.00	1.00	2.00	2.00
Operating Expenses	10.0%	41,059	37,328	31,119	27,657	30,031	26,276	23,484	17,474	16,400	14,737	12,638	8,435	5,857	3,499	1,135	295
S&GA Expenses	-100.0%	-	6,462	5,772	5,719	5,636	5,737	5,242	4,892	5,050	3,649	4,752	3,211	2,059	1,167	346	79.00
R&D Expenses	9.4%	33,776	30,866	25,347	21,938	24,395	20,539	18,242	12,582	11,350	11,088	7,886	5,224	3,798	2,332	789	216
Net Income	-12.0%	-39,061	-34,884	-28,429	-24,891	-29,051	-25,314	-22,890	-17,258	-16,366	-14,710	-12,606	-8,399	-5,852	-3,498	-1,135	-293
Net Income Margin	2.6%	-12.86*	-13.20*	-14.56*	-19.27*	-34.34*	-45.31*	-81.77*	-197.22*	-403.73*	-415.67*	-410.20*	-375.18*	-404.17*	-1.77	-	-
Free Cashflow	-40.4%	-32,065	-22,845	-23,938	-26,229	-26,950	-20,913	-16,745	-15,700	-10,089	-16,192	-11,028	-7,247	-4,142	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-15.7%	168	200	225	249	113	129	145	162	175	186	199	210	60.00	63.00
Current Assets	-17.6%	148	179	203	226	89.00	118	139	154	167	177	191	201	48.00	62.00
Cash Equivalents	-17.9%	145	177	199	223	86.00	112	132	148	156	146	157	166	19.00	62.00
Net PPE	-6.8%	5.00	5.00	6.00	6.00	6.00	6.00	3.00	3.00	3.00	3.00	3.00	1.00	0.00	0.00
Liabilities	8.1%	33.00	31.00	25.00	24.00	30.00	21.00	14.00	11.00	10.00	7.00	8.00	8.00	4.00	2.00
Current Liabilities	10.5%	25.00	23.00	16.00	14.00	19.00	19.00	13.00	9.00	8.00	5.00	6.00	5.00	4.00	2.00
Shareholder's Equity	-20.0%	135	169	200	224	83.00	109	131	150	165	179	191	202	0.00	5.00
Retained Earnings	-15.7%	-287	-248	-213	-185	-160	-131	-106	-83.40	-66.10	-49.74	-35.03	-22.43	-14.00	-8.18
Additional Paid-In Capital	1.2%	423	418	414	410	244	240	237	234	231	229	226	224	14.00	13.00
Shares Outstanding	0.1%	36.00	36.00	36.00	35.00	30.00	30.00	29.00	29.00	29.00	24.00	29.00	25.00	12.00	-
Float	-	-	-	-	597	-	-	-	256	-	-	-	236	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-40.3%	-32,030	-22,837	-23,899	-25,812	-24,044	-20,201	-16,795	-15,427	-9,994	-15,899	-8,988	-6,476	-4,075	-2,736	-1,102	-369	-252	-
Share Based Compensation	30.0%	5,022	3,864	3,598	3,436	3,233	2,716	2,731	2,559	2,330	1,931	1,921	1,463	919	-	-	-	-	-
Cashflow From Investing	-337.5%	-35.00	-8.00	-39.00	-417	-1,756	-701	225	7,375	20,442	4,550	-75.00	680	-38,510	-	-	-	-	-
Cashflow From Financing	-81.4%	116	622	138	162,837	201	490	400	318	31.00	246	-	152,942	-3.00	56,388	-	9,528	50.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BMEA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 33,776	$ 24,395
General and administrative	7,283	5,636
Total operating expenses	41,059	30,031
Loss from operations	(41,059)	(30,031)
Interest and other income, net	1,998	980
Net loss	(39,061)	(29,051)
Other comprehensive loss:
Unrealized gain (loss) on investments, net		1
Comprehensive loss	$ (39,061)	$ (29,050)
Net loss per common share, basic	$ (1.09)	$ (0.98)
Net loss per common share, diluted	$ (1.09)	$ (0.98)
Weighted-average number of common shares used to compute basic net loss per common share	35,890,370	29,586,468
Weighted-average number of common shares used to compute diluted net loss per common share	35,890,370	29,586,468

BMEA Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 144,918	$ 176,866
Prepaid expenses and other current assets	2,648	2,315
Total current assets	147,566	179,181
Property and equipment, net	4,806	5,159
Operating lease right-of-use assets	9,013	9,714
Restricted cash	369	370
Other assets	6,740	5,503
Total assets	168,494	199,927
Current liabilities:
Accounts payable	4,709	6,851
Accrued expenses and other current liabilities	17,379	13,543
Operating lease liabilities, current	3,166	2,466
Total current liabilities	25,254	22,860
Operating lease liabilities, non-current	7,926	7,830
Total liabilities	33,180	30,690
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31,2024 and December 31, 2023
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 35,933,586 and 35,866,610 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	423,196	418,058
Accumulated deficit	(287,886)	(248,825)
Total stockholders' equity	135,314	169,237
Total liabilities and stockholders' equity	$ 168,494	$ 199,927

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

CEO	Mr. Thomas Andrew Butler
WEBSITE	https://biomeafusion.com
INDUSTRY	Biotechnology
EMPLOYEES	94

Biomea Fusion, Inc. Frequently Asked Questions

What is the ticker symbol for Biomea Fusion, Inc.? What does BMEA stand for in stocks?

BMEA is the stock ticker symbol of Biomea Fusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biomea Fusion, Inc. (BMEA)?

As of Mon May 13 2024, market cap of Biomea Fusion, Inc. is 411.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMEA stock?

You can check BMEA's fair value in chart for subscribers.

What is the fair value of BMEA stock?

You can check BMEA's fair value in chart for subscribers. The fair value of Biomea Fusion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biomea Fusion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMEA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biomea Fusion, Inc. a good stock to buy?

The fair value guage provides a quick view whether BMEA is over valued or under valued. Whether Biomea Fusion, Inc. is cheap or expensive depends on the assumptions which impact Biomea Fusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMEA.

What is Biomea Fusion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, BMEA's PE ratio (Price to Earnings) is -3.23 and Price to Sales (PS) ratio is 41.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMEA PE ratio will change depending on the future growth rate expectations of investors.